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Background: Hyperglycaemia during and after hip surgery is associated with coagulation activation and an in-
creased risk of venous thromboembolism.Whether lowering of glucose levels during hip surgery diminishes co-
agulation activation is unknown. We investigated the efﬁcacy of the human GLP-1 analogue liraglutide to lower
glucose during and after hip surgery and studied its inﬂuence on coagulation activation.
Methods: A total of 37 obese subjects who underwent hip surgery were randomized to subcutaneous liraglutide
or placebo for 4 consecutive days, starting one day prior to surgery. Glucose levels and coagulation indices at
three ﬁxed time-points (pre-operative, 2 h post-operative and 3 days post-operative) were measured.
Results: Liraglutide reduced glucose at day three post-surgery (median glucose (IQR) liraglutide 5.5 (5.2–5.7) vs.
placebo 5.8 (5.5–6.2); difference 0.3 mmol/L, P=0.04). Changes in 6 out of 8 coagulation indices studied did not
differ between the two groups. Only D-dimer levels were signiﬁcantly lower in the liraglutide group at day three
post-surgery and FVIII levels were signiﬁcantly higher in the liraglutide group 2 h post-surgery.
Conclusion: Although the human GLP-1 analogue liraglutide moderately reduced post-operative blood glucose
levels in non-diabetic and prediabetic obese patients undergoing elective hip surgery, no changeswere observed
with respect to coagulation activation.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients undergoing hip surgery have a risk to develop postoperative
venous thromboembolism (VTE). It is estimated that symptomatic VTE
occurs in approximately 0.5 to 2.0% of patients, even if adequate
thromboprophylaxis is provided [1,2]. While the procedure-related
tissue damage is the major activator of coagulation, several risk
factors, such as postoperative immobilization, increasing age and
high body mass index, have been associated with a higher incidence
of VTE [3]. In addition, we have recently shown that post-surgical
‘stress-induced’ hyperglycaemia in patients undergoing elective hipicine, F4-257, AcademicMedical
rlands. Tel.: +31 20 5663637;
. Sechterberger),
olvg.nl (R.W. Poolman),
ijers), j.b.hoekstra@amc.uva.nl
.
. This is an open access article undersurgery is associated with an increased risk for symptomatic VTE, inde-
pendent of diabetes mellitus and other confounders [4].
That surgery itself can precipitate acute hyperglycaemia, or ‘stress
hyperglycaemia’, is well known and appears to be due to alteration of
endogenous hormone production and metabolites [5]. Growing evi-
dence supports the hypothesis that ‘stress hyperglycaemia’ leads to a
hypercoagulable and hypoﬁbrinolytic state [6]. In experimental settings
aswell as in patientswith diabetes, hyperglycaemia contributes to coag-
ulation activation and downregulation ofﬁbrinolytic activity, as demon-
strated by increased levels of several procoagulant factors, such as
thrombin–antithrombin (TAT) complexes, soluble tissue factor, ﬁbrino-
gen, vonWillebrand (vWF), factor VII, factor VIII and decreased levels of
antiﬁbrinolytic factors (plasminogen activator inhibitor-1 (PAI-1))
[7–9]. Moreover, hip surgery in patients without diabetes mellitus has
been shown to induce hyperglycaemia peaking the days after the proce-
dure, which was followed by a rise of factor VIII, vWF and prothrombin
fragment 1 + 2 (F1 + 2) [10].
In diabetic patients, the effect of hyperglycaemia on coagulation
seems to be modiﬁable, as improvement of glycaemic control amongthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Whether establishing glycaemic control during hip surgery will inﬂu-
ence the coagulation activation is unknown.
Insulin therapy is the most widely used method to induce glycaemic
control. However, insulin therapy is time consuming and is accompanied
by an increased risk of hypoglycaemia,which is related to seriousmorbid-
ity [13]. The human glucagon-like peptide-1 (GLP-1) analogue liraglutide
is an alternative glucose lowering agent which acts in a glucose-
dependent manner, i.e. it stimulates insulin secretion only when blood
glucose levels are above normal. Consequently, it has negligible risk of
hypoglycaemia [14]. In the current study we aimed to investigate the
efﬁcacy of the human GLP-1 analogue liraglutide to lower glucose during
and after hip surgery and its inﬂuence on coagulation activation.
2. Matherials and methods
2.1. Study design and participants
This was a randomized, double-blind, placebo-controlled trial per-
formed at the orthopaedic department of a teaching hospital (Onze
Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) involving 37 pa-
tients. Participantswere recruited between August 2012 and September
2013. Inclusion criteriawere:men andwomenbetween 18 and 75years
of age, scheduled for elective hip surgery, dabigatran used as anticoagu-
lant drug after surgery and signed informed consent. Exclusion criteria
were: type 1 or type 2 diabetes mellitus, use of oral corticosteroids,
use of Vitamin K antagonists, known coagulation disorders, known
active cancer, a history of chronic pancreatitis or idiopathic acute pan-
creatitis, impaired liver function (deﬁned as alanine aminotransferase
(ALAT) 2.5 times upper normal limit) or renal function (deﬁned as
serum-creatinine 133 μmol/L for males and 115 μmol/L for females),
females of child bearing potential who are pregnant or breast-feeding
and spinal anaesthesia. The study protocol was approved by the institu-
tional review board (medical ethical committee of the Academic Medi-
cal Center, Amsterdam and Onze Lieve Vrouwe Gasthuis, Amsterdam).
All participants provided written informed consent. This trial is regis-
tered at the Dutch trial register, www.trialregister.nl, number NTR3547.
2.2. Study procedures
Participants were randomized to receive either liraglutide or
matching placebo by block randomisation (block size was 4) via a pre-
generated ﬁxed list with successive numbered treatment options. Both
participants and investigators were blinded to treatment assignment.
Treatment with liraglutide (0.6 mg) or placebo started one day prior to
surgery. Participants underwent dose escalation to 1.2 mg/day at the
day of surgery until day 3 post-operative. Liraglutide (6.0 mg/mL)
and placebo were provided in identical FlexPen® devices (Novo
Nordisk A/S, Bagsværd, Denmark) and were given by subcutaneous
injection in the abdomen at 5 pm daily. Adverse events were recorded
daily by study personnel. The total planned treatment period was
4 days. All participants received general anaesthesia and identical
anti-emetic prophylaxis (droperidol 0.625 mg during induction,
granisetron 1mg post-operatively). None of the subjects received corti-
costeroids. Venous blood samples for laboratory tests were taken at 3
ﬁxed points in time (before induction of anaesthesia, 2 h after the end
of surgery and three days post-operative. All blood samples were
taken by venapuncture in the fasting state. In all participants, 220 mg
dabigatran once-daily in the morning starting from the day after sur-
gery was given as thromboprophylaxis. All subjects were allowed to re-
sume their daily diet when they were transferred to the surgical ward.
2.3. Outcome measures
The primary outcome was the difference in glucose at day 3 post-
surgery between the study groups. Secondary outcomes were thedifference in coagulation indices at day 3 post-surgery and included
prothrombin fragment 1+ 2 (F1+ 2), thrombin–antithrombin com-
plex (TAT), plasmin–alpha2-antiplasmin complex (PAP), D-dimer,
coagulation factor VIII (FVIII), von Willebrand factor (vWF), anti-
thrombin (AT) and plasminogen activator inhibitor-1 (PAI-1).2.4. Laboratory assessments
All blood samples were centrifuged within 1 h at 1500 g at 4 °C for
10 min, plasma was separated (separated plasma of citrate samples was
centrifuged again for 10 min) and stored immediately at−70 °C. Plasma
glucose concentrations were measured with a glucose hexokinase meth-
od (Roche/Hitachi, Indianapolis, USA). D-dimer, factor VIII activity and AT
were measured on an automated coagulation analyser (Siemens BCS-XP
system) using protocols and reagents from the manufacturer (Siemens
Healthcare Diagnostics, Marburg, Germany). Antigen levels of vWF were
assayed by ELISA using antigens from DAKO (Heverlee, Belgium).
F1 + 2 and TAT were determined by ELISA from Siemens Healthcare
Diagnostics, PAI-1 was determined by ELISA from BioMed and PAP was
determined by ELISA from DRG diagnostica (Marburg, Germany).2.5. Statistical analysis
The study was powered to detect a difference (± SD) of 1.0 ±
0.8 mmol/L in glucose three days post-surgery between the two study
groups. This difference was based on a 2 mmol/L increase in glucose
level in a prior study [10] and an expected 50% reduction in glucose
with use of liraglutide. Taking into account a drop-out rate of 10%, the
sample size calculation indicated that 18 patients per groupwere need-
ed in order to detect the effect on glucose between the two study groups
with 80% power and an alpha level of 0.05. Analyses were based on the
intention-to-treat principle. Data of the patients who were withdrawn
from the study before day three post-surgerywere used for the analyses
as far as possible. Results are expressed as percentages for categorical
variables, mean and standard deviation (SD) for continuous normally
distributed variables, andmedian and interquartile range (IQR) for con-
tinuous non-normally distributed variables. Groups were compared by
using Fisher's Exact test, Student's t test or Mann Whitney rank-sum
test where appropriate. Primary and secondary outcomes were
analysed by use of the Mann Whitney rank-sum test. In addition,
mixed between-within ANOVA analyses were performed to assess the
treatment effect over time. A secondary analysis was performed to as-
sess the inﬂuence of surgery-induced stress on coagulation. Data from
the placebo groupwere used to assess equality of the laboratory param-
eters at three time points using the Friedman test. Where the Friedman
test resulted in statistical signiﬁcance, subsequent testswere performed
using theWilcoxon Signed rank test. All analyses were performed using
PASW statistics software version 20.0 (SPSS Inc, Chicago, IL, USA); a P-
value of b0.05 was considered statistically signiﬁcant.3. Results
In total, 37 patients were randomized and 36 received studymed-
ication in the trial. Thirty-two patients completed the trial (Fig. 1).
One patient withdrew informed consent prior to start of treatment
and was replaced. Two patients in the liraglutide group withdrew
from the study due to adverse events (moderate/severe nausea,
starting at the dose of 1.2 mg/day). Furthermore, in each study-
group one patient discontinued the study due to non-compliance
with the protocol (not willing to undergo blood sampling). Baseline
characteristics are summarized in Table 1. More women were ran-
domized to the placebo group, which did not reach statistical signif-
icance. Most patients included in the trial were overweight (average
BMI of 28 kg/m2).
Fig. 1. Flow chart of study participants; assessment, randomization and analysis.
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Plasma glucose levels per time point per treatment group are
depicted in Fig. 2. Glucose at day three post-surgery was signiﬁcantlyTable 1
Baseline characteristics of the patients included in the trial.
Liraglutide
(n= 19)
Placebo
(n= 17)
Age—years (mean ± SD) 57 ± 12 59 ± 11
Sex, female n (%) 9 (47) 13 (77)
Body-mass index—kg/m2 (mean ± SD) 28 ± 5 27 ± 5
Ethnic origin, n (%)
- White 16 (84) 17 (100)
- Surinam/Antilian 2 (11) –
- Other 1 (5) –
Reason surgery, n (%)
- Coxarthrosis 18 (95) 16 (94)
- Other 1 (5) 1 (6)
Type of hip implant ﬁxation, n (%)
- Cemented 12 (63) 10 (59)
- Cementless 3 (16) 3 (18)
- Hybrida 4 (21) 4 (23)
Relevant medical history, n (%)
- Cardiovascular disease – –
- COPD/asthma 2 (11) 1 (6)
- History of VTE – –
HbA1c—mmol/mol (mean ± SD) 38 ± 3 36 ± 3
Duration of surgery in minutes (mean ± SD) 89 ± 23 101 ± 27
COPD: chronic obstructive pulmonary disease; VTE: venous thrombo-embolism; HbA1c:
glycated haemoglobin.
a Cup inserted without cement, stem inserted with cement.lower in the liraglutide group (median glucose (IQR) liraglutide 5.5
(5.2–5.7) vs. placebo 5.8 (5.5–6.2); difference 0.3 mmol/L, P = 0.04).
However, liraglutide treatment did not signiﬁcantly reduce glucose
levels during the full treatment period (P= 0.36).
3.2. Coagulation markers
Fig. 3 shows coagulation indices per time point per treatment group.
A signiﬁcant difference between the groups was only found in D-dimer
levels at day three post-surgery (median D-dimer (IQR) liraglutide 1.5
(1.2–1.9) vs. placebo 1.9 (1.6–2.4); difference−0.4 mmol/L, P= 0.04)Fig. 2.Median peri-operative glucose levels with interquartile range per treatment group.
*P b 0.05.
Fig. 3. Coagulationmarkers per treatment group during the study period. F1+ 2: prothrombin fragment 1+ 2; TAT: thrombin–antithrombin complex. PAP: plasmin alpha2-antiplasmin
complex; vWF: von Willebrand Factor; AT: antithrombin; PAI-1: plasminogen activator inhibitor-1. All data are median with interquartile range. * P b 0.05.
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(163–243) vs. placebo 132 (118–215); P= 0.04). However, liraglutide
treatment did not signiﬁcantly change D-dimer levels (P = 0.56) and
FVIII levels (P= 0.28) during the full treatment period.3.3. Adverse events
The reported adverse events during the trial are shown in Table 2.
Common adverse events in the liraglutide group were nausea (47%)
Table 2
Adverse events reported during the treatment period.
Liraglutide (n= 19) Placebo (n= 17) P-value
Nausea 9 (47%) 5 (29%) 0.32
Vomiting 3 (16%) – 0.23
Loss of appetite 4 (21%) 1 (6%) 0.34
Dizziness 3 (16%) 1 (6%) 0.61
Headache 2 (11%) 1 (6%) 1.0
Reaction injection location – 1 (6%) 0.47
Vasovagal collapse 1 (5%) – 1.0
Diarrhoea – – –
No adverse events reported 7 (37%) 10 (59%) 0.32
231M.K. Sechterberger et al. / BBA Clinical 3 (2015) 227–232and loss of appetite (21%). In the placebo group nausea occurred in 29%
of patients. No statistical differences were found between the groups.
3.4. Inﬂuence of surgery-induced stress on glucose levels and coagulation
indices
In the placebo group, glucose levels 2 h post-operatively signiﬁcantly
increased compared to pre-operative glucose levels (Table 3). With
regard to coagulation, F1 + 2, TAT, PAP and D-dimer signiﬁcantly in-
creased and AT signiﬁcantly decreased during the post-operative pe-
riod. FVIII and vWF were signiﬁcantly increased at day three post-
operatively, but not 2 h post-operatively (Table 3).
4. Discussion
The present study shows that the human GLP-1 analogue liraglutide
moderately reduced post-operative blood glucose levels with
0.3 mmol/L in nondiabetic and prediabetic patients undergoing elec-
tive hip surgery. However, this decrease in glucose levels did not in-
ﬂuence coagulation activation.
Little is known about the impact of hospital-related hyperglycaemia
in non-diabetic orthopaedic patients. Richards et al. performed a
prospective observational study in stable non-diabetic patients with
orthopaedic injuries and showed that stress hyperglycaemia was
associated with surgical site infection [15]. However, randomized trials
evaluating hyperglycaemia treatment in hospitalized non-diabetic,
non-critically ill patients are lacking. This investigation is the ﬁrst ran-
domized trial that focused on the treatment of postsurgical stress-
induced hyperglycaemia in an orthopaedic non-diabetic population.
Interestingly, despite the presence of obesity and prediabetes, in
both treatment groups only 25% (n= 4 in each group) of the patients
exceeded the threshold of stress-induced hyperglycaemia postopera-
tively as deﬁned by Dungan et al. (fasting glucose N 6.9 mmol/L) [5].
In addition, none of the patients were hyperglycaemic three days
post-surgery. These ﬁndings are different from our previous observa-
tional study, in which we found increased (non-fasting) mean glucose
levels (N7.8 mmol/L) postoperatively from the second postoperativeTable 3
Peri-operative glucose and coagulation indices at all time-points (placebo group). All data is pre
riods per laboratory assessment was determined by the Friedman Test.
Pre-operative (n= 17) 2 hrs post-ope
Glucose (mmol/L) 5.8 (5.2–6.0) 6.3 (5.8–6.9)
F1 + 2 (pMol/L) 271 (207–308) 963 (810–13
TAT (μg/L) 4.2 (3.6–5.8) 38.9 (24.5–54
PAP (μg/L) 595 (401–675) 1692 (1104–2
D-dimer (mg/L FEU) 0.7 (0.5–1.1) 11.9 (10.2–17
FVIII (%) 163 (124–187) 132 (118–21
vWF (%) 128 (104–158) 113 (94–181
AT (%) 114 (104–122) 97 (84–101
PAI-1 (ng/mL) 10.3 (6.2–15.7) 8.7 (4.9–18.0
⁎P b 0.05, †P b 0.01, ‡P b 0.001 compared to pre-operative levels, in post-hoc analysis. F1 + 2: pr
antiplasmin complex; vWF: von Willebrand factor; AT: antithrombin; PAI-1: plasminogen actiday up to the 4th day after surgery [10]. In order to explain these con-
ﬂicting resultswe compared baseline- and treatment characteristics be-
tween the studies. Patients included in the previous study were on
average 4 years older, the mean duration of surgery was longer (121
vs 101min), their BMI was one point higher and half of the patients re-
ceiveddexamethasone as anti-emeticum,which causes hyperglycaemia
post-operatively [16]. Whether these differences do explain the lower
rate is unclear.
Overall, our current study population consisted of overweight indi-
viduals, with an average BMI of 28 kg/m2. It is known that obesity is
common among patients undergoing hip replacement surgery. More-
over, obesity is a clear risk factor for developing osteoarthritis, the
most common indication for hip replacement surgery [17].
Interestingly, 14 of 36 patients (39%) had prediabetes glycated
haemoglobin levels (between 38–46mmol/mol), thus being ‘prediabet-
ic’. Twenty-one patients (58%) had glycated haemoglobin levels below
38 mmol/mol and one patient had a glycated haemoglobin level of
47 mmol/mol. With regard to pre-operative fasting glucose levels, 17
of 36 patients (47%) had blood glucose levels between 5.6 and
6.9 mmol/L, thus impaired fasting glucose. It should be mentioned
that all patients already received the study-therapy, either verum or
placebo, no off-treatment baseline values were available. Only 5 of the
17 patients (29%) who had impaired fasting glucose levels also had
HbA1C-levels in the prediabetic range. Perhaps, blood glucose-levels
at the day of surgery are already increased due to stress related to the
upcoming procedure.
The fact that we did not ﬁnd a marked increase in glucose levels in
the placebo group during the treatment period may have contributed
to the small difference in glucose levels (0.3mmol/L) between the treat-
ment groups three days post-operatively. The smaller difference in glu-
cose levels found in this study may also explain that no clear difference
in coagulation indices was observed. Thus, a clear causal relationship
between glucose and coagulation activation could not be conﬁrmed
with the present study. Results should therefore be interpreted with
caution. The statistical difference found in D-dimer- and FVIII-levels
may have been multiple testing results and one can argue whether
these changes are biologically relevant.
That the surgical procedure activates coagulation is clearly demon-
strated by the increase of D-dimer, F1 + 2 and TAT and the decrease
in AT post-operatively. Our ﬁndings are in line with previous studies
which assessed coagulation activation in orthopaedic surgery [10,18].
Other causes, such as bleeding or vascular damage induced by surgery
are more likely to have inﬂuenced these coagulation parameters than
the relatively modest increase in glucose.
Our study has several limitations. First, onemay debate the dose es-
calation and treatment duration used in this study. In diabetes patients
treated with GLP-1, dose escalation from the starting dose (0.6 mg/day)
to 1.2mg/day is applied at least after oneweek of GLP-1 treatment, part-
ly in order to reduce the risk of gastrointestinal side effects. In addition,
steady-state pharmacokinetics for liraglutide is reached after three dayssented as median (25th–75th percentile). The statistical change across the three time pe-
rative (n= 16) Day 3 post-operative (n= 16) P value
† 5.8 (5.5–6.2) 0.003
26)‡ 436 (287–572)‡ b0.001
.6)‡ 11.1 (8.6–14.8)⁎ b0.001
889)† 667 (623–753)⁎ b0.001
.3)‡ 2.0 (1.6–2.4)† b0.001
5) 235 (207–271)† 0.001
) 232 (189–250)‡ b0.001
)‡ 101 (98–112)† b0.001
) 9.4 (4.9–11.4) 0.41
othrombin fragment 1+ 2; TAT: thrombin–antithrombin complex; PAP: plasmin alpha2–
vator inhibitor-1.
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perioperative blood glucose lowering strategy were available, we con-
sidered that the proof-of-principle dosing regimen designed for the cur-
rent study was a good compromise between titrating too fast, which
was likely to result in many side effects, and underdosing, which was
likely to give suboptimal glucose lowering. Starting liraglutide earlier
before surgery did not seem attractive, as these patients would not be
hyperglycaemic before surgery.
Second, the placebo group consisted of a non-signiﬁcantly larger
number of female subjects compared to the liraglutide group, despite
of the randomisation procedure. In order to assess any effect modiﬁ-
cation by sex, analyses were also performed for each gender sepa-
rately. There could perhaps be a minimally larger effect in glucose
lowering in females (difference in median glucose 0.4 mmol/L, P =
0.02) than in males (difference in median glucose 0.3 mmol/L, P =
0.26). It should be noted that comparisons for each gender separate-
ly were based on a very small sample size. So this difference should
be interpreted cautiously, since it could be the result of random
error or confounding.
Third, all laboratory assessments were performed when patients
were already on treatment. Therefore, wewere not able to include base-
line values without treatment as covariate in our analyses. As all sub-
jects who were participating in this trial were non-diabetic, glucose
valueswere expected to be in normal range and taking a fasting baseline
sample before hospital admission was not feasible.
Finally, theuse of dabigatran as thromboprophylaxismayhave inﬂu-
enced the levels of several coagulation markers when patients did re-
ceive thromboprophylaxis [20]. However, all subjects in our trial
received identical anticoagulant therapy, so dabigatran would have af-
fected both groups similarly.
5. Conclusion
The use of the humanGLP-1 analogue liraglutide in non-diabetic and
prediabetic patients undergoing elective hip surgery moderately re-
duced post-operative blood glucose levels but did not change coagula-
tion activation.
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